anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

216,541-216,600 of 319,975

filter-aware
72
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
73
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
74
Includes code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
75
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
76
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
77
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
78
The slide uses a process flow framework to show the integration of AI across the drug development lifecycle.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
79
The slide outlines a proprietary workflow combining AI-driven design with experimental validation.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
80
The slide uses a split-screen layout to contrast project objectives with results.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
81
The slide uses a dot plot to show binding affinity vs sequence diversity and a bar chart to compare binding rates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
82
The slide shows two dose-response curves (Cell Surface Binding and ADCC) and two molecular surface models for epitope mapping.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
83
The slide uses a Gantt-style chart to illustrate the overlap of two batches of targets.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
84
The slide uses a process flow framework to show the progression from target discovery to optimized antibodies.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
85
The slide features a circular flywheel diagram on the left and a breakdown of the wet lab validation process on the right.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
86
The slide uses molecular visualization of RBD mutations and a table showing KD (binding affinity) values, highlighting the poor binding (607 nM) to the beta variant.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
87
The slide uses a two-step process flow (1 and 2) to explain the technical methodology of their AI-driven drug discovery platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
88
The slide uses a process flow (1 -> 2) followed by a scatter plot validation and a summary table of Pearson R values.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
89
SPR stands for Surface Plasmon Resonance. The charts show binding affinity (KD) comparisons.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
90
The slide uses a process diagram to show the AI workflow and a table to quantify the binding affinity (nM KD) improvements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
91
The slide uses a consistent visual metaphor of a Y-shaped antibody binding to three distinct targets in each of the three columns.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
92
The slide uses a 5-column layout with icons to represent different capabilities of the platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
93
Includes pseudo-code snippets in the background.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
94
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
95
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
96
The chart uses a horizontal bar format to represent development progress. Color coding distinguishes between 'Potential First in Class' (blue) and 'Potential Best in Class' (red).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
97
Includes a biological pathway diagram (Takedatsu 2008) and market data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
98
The scatter plot shows a Pearson R of 0.74 for N=5389 data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
99
The chart is a dot plot showing affinity (KD) vs edit distance from parent binder. The benchmark is a horizontal dashed line.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
100
The slide uses a side-by-side comparison structure to detail the value proposition of two specific drug candidates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
101
The slide illustrates a dual-pathway process leading to a unified AI-driven optimization step.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
102
Includes a Kaplan-Meier survival curve and a biological diagram of TLS.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
103
The slide outlines a proprietary R&D workflow for antibody discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
104
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
105
The slide illustrates a scientific workflow for target discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
107
The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
108
The chart uses a horizontal bar format to represent development progress against a timeline of stages (Target Eval to IND).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
109
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
110
The slide uses code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
111
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
01
Slide 1
The slide features a split design with a white left side containing logos and a dark purple abstract background on the right.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a Gantt-style chart to show the development stage of multiple drug programs.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
04
The slide uses a three-column layout to compare product candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
08
The slide uses a split-screen layout with a photo of a person on the right and branding on the left.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
11
Pharmacokinetic study results showing extended half-life for the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
12
The slide outlines a standard clinical trial progression for SAD and MAD cohorts, including randomization ratios and participant types.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
13
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
14
Includes PK modeling data comparing human and NHP half-lives and steady-state concentration simulations.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
16
The slide uses a bar chart to show dose-response correlation and a line chart to show pharmacokinetic modeling.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
18
The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
19
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
20
Features a stylized antibody icon overlay on a photo of a person.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit